Fusion Antibodies PLC Block listing Interim Review (0081V)

TIDMFAB

RNS Number : 0081V

Fusion Antibodies PLC

03 April 2023

3 April 2023

Fusion Antibodies plc

("Fusion" or the "Company")

Block admission six monthly return

Fusion Antibodies plc (AIM: FAB), a contract research organisation providing discovery, design, and optimisation services for therapeutic antibodies to the global healthcare market, announces the following information in connection with its block admission pursuant to AIM Rule 29 and Schedule Six of the AIM Rules for Companies.

 
 Name of company:                     Fusion Antibodies plc 
 Name of scheme:                      Historic options, EMI and Unapproved 
                                       Employee Share Option Scheme, 
                                       as announced on 27 September 
                                       2021 
                                     -------------------------------------- 
 Period of return:                    From 2 October 2022 to 1 April 
                                       2023 
                                     -------------------------------------- 
 Number and class of securities       757,083 ordinary shares of 4 
  not issued under the scheme          pence each in the Company ("Ordinary 
  at the beginning of the period:      Shares") 
                                     -------------------------------------- 
 Number of securities issued          Nil 
  under the scheme during the 
  period: 
                                     -------------------------------------- 
 Number of options under the          Options over 5000 Ordinary Shares 
  scheme that have lapsed during 
  the period: 
                                     -------------------------------------- 
 Balance under the scheme of          752,083 Ordinary Shares 
  securities not yet issued at 
  the end of the period: 
                                     -------------------------------------- 
 Number and class of securities       917,083 Ordinary Shares on 27 
  originally admitted and the          September 2021 
  date of admission: 
                                     -------------------------------------- 
 Contact name and telephone number:   James Fair, CFO via Walbrook 
                                       PR 
                                       [phone] 
                                     -------------------------------------- 
 

Enquiries:

 
 Fusion Antibodies plc                                  www.fusionantibodies.com 
 Adrian Kinkaid, Chief Executive Officer                         Via Walbrook PR 
  James Fair, Chief Financial Officer 
 
 Allenby Capital Limited                                     Tel: [phone] 
                                                                            5656 
 James Reeve/Vivek Bhardwaj (Corporate 
  Finance) 
  Tony Quirke/Joscelin Pinnington (Sales 
  and Corporate Broking) 
 
 Walbrook PR                 Tel: [phone] or [e-mail] 
 Anna Dunphy                                                Mob: [phone] 
                                                                             001 
 
 

About Fusion Antibodies plc

Fusion is a Belfast based contract research organisation ("CRO") providing a range of antibody engineering services for the discovery and development of antibodies for both therapeutic drug and diagnostic applications.

The Company's ordinary shares were admitted to trading on AIM on 18 December 2017. Fusion provides a broad range of services in antibody design, generation, development, production, characterisation and optimisation. These services include antigen expression, antibody production, purification and sequencing, antibody humanisation using Fusion's proprietary CDRx (TM) platform and the production of antibody generating stable cell lines to provide material for use in clinical trials. Since 2012, the Company has successfully sequenced and expressed over 250 antibodies and successfully completed over 200 humanisation projects and has an international, blue-chip client base, which has included eight of the top 10 global pharmaceutical companies by revenue.

The Company was established in 2001 as a spin out from Queen's University Belfast. The Company's mission is to enable pharmaceutical and diagnostic companies to develop innovative products in a timely and cost-effective manner for the benefit of the global healthcare industry.

Fusion Antibodies growth strategy is based on combining the latest technological advances with cutting edge science to deliver new platforms that will enable Pharma and Biotech companies get to the clinic faster, with the optimal drug candidate and ultimately speed up the drug development process.

The global monoclonal antibody therapeutics market was valued at $135.4 billion in 2018 and is forecast to surpass $212.6 billion in 2022, an increase at a CAGR of 12.0 per cent. for the period 2018 to 2022. In 2017, seven of the world's ten top selling drugs were antibody-based therapeutics with the combined annual sales of these drugs exceeding $63.2 billion.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

BLRZFLFXXXLZBBK

(END) Dow Jones Newswires

April 03, 2023 02:00 ET (06:00 GMT)